{"transactions":[{"id":948185,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T20:00:11.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000149315226000703/ownership.xml","form_type":"4"}},{"id":1296688,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-01-23T17:00:43.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":78741,"derivative":{"exercise_price":1.27,"underlying":"Common Stock","underlying_shares":78741},"source":{"system":"sec-edgar","filing":"0001654954-25-000690","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495425000690/section16.xml","form_type":"4"}},{"id":1296687,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T17:00:43.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":80957,"source":{"system":"sec-edgar","filing":"0001654954-25-000690","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495425000690/section16.xml","form_type":"4"}},{"id":1303845,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T18:56:40.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000410","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495425000410/section16.xml","form_type":"4"}},{"id":1471205,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-06-24T16:05:08.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":3300,"derivative":{"exercise_price":8.1,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0000950170-24-076698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000095017024076698/ownership.xml","form_type":"4"}},{"id":1616880,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T17:03:15.000Z","date":"2024-02-23","kind":"purchase","planned":false,"acquired":true,"shares":266,"price":9.04,"value":2404.64,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024."}],"balance_after":29673,"source":{"system":"sec-edgar","filing":"0001209191-24-004016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919124004016/doc4.xml","form_type":"4"}},{"id":1616879,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T17:03:15.000Z","date":"2024-02-23","kind":"purchase","planned":false,"acquired":true,"shares":714,"price":9.04,"value":6454.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024."}],"balance_after":714,"source":{"system":"sec-edgar","filing":"0001209191-24-004016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919124004016/doc4.xml","form_type":"4"}},{"id":1686178,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-05T21:00:57.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000293","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495424000293/section16.xml","form_type":"4"}},{"id":1841382,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-06-30T16:00:10.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":0.3553,"expiration_date":"2033-06-28","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-040278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919123040278/doc4.xml","form_type":"4"}},{"id":2140748,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-07T17:06:06.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":30155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 30,155 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":75720,"source":{"system":"sec-edgar","filing":"0001654954-22-013528","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495422013528/section16.xml","form_type":"4"}},{"id":2210172,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-08T16:10:20.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":26441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 26,441 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":45565,"source":{"system":"sec-edgar","filing":"0001654954-22-009455","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000165495422009455/section16.xml","form_type":"4"}},{"id":2228658,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-06-17T18:01:18.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":1.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-22-038041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919122038041/doc4.xml","form_type":"4"}},{"id":2300603,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T19:12:15.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":15466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 15,466 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":19124,"source":{"system":"sec-edgar","filing":"0000905718-22-000562","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571822000562/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2402460,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-11T18:00:21.000Z","date":"2021-10-01","kind":"gift","acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures, LLC"},"balance_after":588152,"source":{"system":"sec-edgar","filing":"0001209191-22-008972","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919122008972/doc5.xml","form_type":"5"}},{"id":2445289,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T19:08:44.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000048","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571822000048/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2477688,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-10T17:04:17.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":71,"price":4.0664,"value":288.7144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported herein were made for tax planning purposes."}],"balance_after":796,"source":{"system":"sec-edgar","filing":"0001209191-21-069092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919121069092/doc4.xml","form_type":"4"}},{"id":2477687,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-10T17:04:17.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":11,"price":4.0717,"value":44.7887,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported herein were made for tax planning purposes."}],"balance_after":101,"source":{"system":"sec-edgar","filing":"0001209191-21-069092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919121069092/doc4.xml","form_type":"4"}},{"id":2477686,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-10T17:04:17.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":363,"price":4.0602,"value":1473.8526,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported herein were made for tax planning purposes."}],"balance_after":3114,"source":{"system":"sec-edgar","filing":"0001209191-21-069092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919121069092/doc4.xml","form_type":"4"}},{"id":2600996,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":35714,"ownership":{"direct":false,"nature":"By Hale Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Reporting Person purchased 35,714 Units in the IPO at $7.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":35714,"derivative":{"exercise_price":7,"exercise_date":"2021-08-17","expiration_date":"2026-08-17","underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600995,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":3048,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3048,"derivative":{"exercise_price":20.5,"exercise_date":"2016-11-15","expiration_date":"2026-03-14","underlying":"Common Stock","underlying_shares":3048},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600994,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1a Warrants","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"exercise_date":"2016-11-15","expiration_date":"2026-03-14","underlying":"Common Stock","underlying_shares":3048},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600993,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":555622,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":27103},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600992,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1c Preferred Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":3571428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":174216},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600991,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1b Preferred Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":410000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600990,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1a Preferred Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12195},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600989,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1d Preferred Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":302112,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44777},"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600988,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":35714,"ownership":{"direct":false,"nature":"By Hale Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Reporting Person purchased 35,714 Units in the IPO at $7.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":35714,"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600987,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":27103,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":532925,"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600986,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":174216,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":505822,"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600985,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":20000,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":331606,"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600984,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":12195,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":311606,"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2600983,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T12:49:46.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":44777,"ownership":{"direct":false,"nature":"By Hale BioVentures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the \"IPO\"). The Series 1d Preferred Stock was convertible at any time and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":299411,"source":{"system":"sec-edgar","filing":"0000905718-21-001110","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000090571821001110/dermata_fm4aug172021.xml","form_type":"4"}},{"id":2629535,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-07-20T16:45:05.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall be 100% vested and exercisable on July 16, 2022."}],"balance_after":10000,"derivative":{"exercise_price":3.77,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-047388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919121047388/doc4.xml","form_type":"4"}},{"id":2645752,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T17:01:16.000Z","date":"2021-06-30","kind":"sale","acquired":false,"shares":3669,"price":4.75,"value":17427.75,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were transferred to Oxford Finance LLC by Hale BioPharma Ventures, LLC in satisfaction of a pledge by Hale BioPharma Ventures, LLC which was previously disclosed by the Issuer."}],"balance_after":713152,"source":{"system":"sec-edgar","filing":"0001209191-21-045049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919121045049/doc4.xml","form_type":"4"}},{"id":2693980,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-05-27T18:06:07.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":5.14,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-21-036313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919121036313/doc4.xml","form_type":"4"}},{"id":3072770,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-07-31T21:06:03.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":2.94,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-20-044381","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120044381/doc4a.xml","form_type":"4/A","original_submission_date":"2020-06-12"}},{"id":3072769,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-07-31T21:05:42.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 reported the acquisition of the Stock Options in the \"D\" column of Column 5.  This amendment is being filed to correctly report the acquisition of the Stock Options in the \"A\" column of Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One thirty-sixth of each Effective Date Award and each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Reporting Persons continued service on the Board through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-20-044372","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120044372/doc4a.xml","form_type":"4/A","original_submission_date":"2019-09-16"}},{"id":3112302,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T21:42:22.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":556,"price":0.555,"value":308.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported herein were made for tax planning purposes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On July 6, 2018, the Issuer effected a 1-for-30 reverse stock split resulting in the reporting person's ownership of 41,295 fewer shares."}],"balance_after":867,"source":{"system":"sec-edgar","filing":"0001209191-20-036491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120036491/doc4.xml","form_type":"4"}},{"id":3112301,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T21:42:22.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":445,"price":0.5545,"value":246.7525,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported herein were made for tax planning purposes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On July 6, 2018, the Issuer effected a 1-for-30 reverse stock split resulting in the reporting person's ownership of 16,179 fewer shares."}],"balance_after":112,"source":{"system":"sec-edgar","filing":"0001209191-20-036491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120036491/doc4.xml","form_type":"4"}},{"id":3112300,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T21:42:22.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":159,"price":0.5578,"value":88.6902,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported herein were made for tax planning purposes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On July 6, 2018, the Issuer effected a 1-for-30 reverse stock split resulting in the reporting person's ownership of 105,463 fewer shares."}],"balance_after":3477,"source":{"system":"sec-edgar","filing":"0001209191-20-036491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120036491/doc4.xml","form_type":"4"}},{"id":3112299,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-06-12T16:39:17.000Z","date":"2020-06-11","kind":"grant","acquired":false,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth of  the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":2.94,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-20-036300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120036300/doc4.xml","form_type":"4"}},{"id":3117237,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-09T14:26:15.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall be 100% vested and exercisable on June 5, 2021."}],"balance_after":500,"derivative":{"exercise_price":0.4797,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001209191-20-035209","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120035209/doc4.xml","form_type":"4"}},{"id":3137818,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-05-22T17:00:12.000Z","date":"2020-05-21","kind":"purchase","acquired":true,"shares":8706,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Securities Purchase Agreement, dated as of May 19, 2020, by and among the Issuer and the several purchasers party thereto, on May 21, 2020 the Reporting Person purchased the securities reported herein for aggregate consideration $44,792.37."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The warrants are currently exercisable."}],"balance_after":8706,"derivative":{"exercise_price":2.51,"expiration_date":"2025-11-21","underlying":"Common Stock","underlying_shares":8706},"source":{"system":"sec-edgar","filing":"0001209191-20-031792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120031792/doc4.xml","form_type":"4"}},{"id":3137817,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-22T17:00:12.000Z","date":"2020-05-21","kind":"purchase","acquired":true,"shares":17412,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Securities Purchase Agreement, dated as of May 19, 2020, by and among the Issuer and the several purchasers party thereto, on May 21, 2020 the Reporting Person purchased the securities reported herein for aggregate consideration $44,792.37."}],"balance_after":716818,"source":{"system":"sec-edgar","filing":"0001209191-20-031792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919120031792/doc4.xml","form_type":"4"}},{"id":3414222,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-09-16T17:40:04.000Z","date":"2019-09-12","kind":"grant","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth of each Effective Date Award and each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Reporting Persons continued service on the Board through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.76,"expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-049691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919119049691/doc4.xml","form_type":"4"}},{"id":3475052,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-01T16:31:01.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.29,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-039725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919119039725/doc4.xml","form_type":"4"}},{"id":3484964,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-06-19T16:23:28.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall be 100% vested and exercisable on June 17, 2020."}],"balance_after":500,"derivative":{"exercise_price":1.02,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001209191-19-038017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919119038017/doc4.xml","form_type":"4"}},{"id":3484963,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-06-19T16:23:28.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on 4/30/19, but was contingent on shareholder approval of an increase in the shares issuable under the Issuer's 2013 Amended and Restated Equity Incentive Plan at the Issuer's annual meeting of stockholders held on 6/17/19, and therefore for purposes of Section 16 the option was not \"acquired\" until such stockholder approval was obtained. 25% of the shares subject to the option shall vest on the first annual anniversary of the Vesting Commencement Date (4/30/19) with the balance vesting in equal monthly installments thereafter until fully vested on 4/30/23"}],"balance_after":30000,"derivative":{"exercise_price":0.91,"expiration_date":"2029-04-29","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-038017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919119038017/doc4.xml","form_type":"4"}},{"id":3494647,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2019-06-11T18:38:30.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":3292,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures, LLC."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The warrants are currently exercisable."}],"balance_after":3292,"derivative":{"exercise_price":6.13,"expiration_date":"2022-09-12","underlying":"Common Stock","underlying_shares":3292},"source":{"system":"sec-edgar","filing":"0000899243-19-016484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000089924319016484/doc4.xml","form_type":"4"}},{"id":3494646,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-11T18:38:30.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":18346,"ownership":{"direct":false,"nature":"By Hale Trading Company."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":18346,"source":{"system":"sec-edgar","filing":"0000899243-19-016484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000089924319016484/doc4.xml","form_type":"4"}},{"id":3494645,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-11T18:38:30.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":699406,"ownership":{"direct":false,"nature":"By Hale BioPharma Ventures, LLC."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the \"Merger Agreement\"), by and among Oncternal Therapeutics, Inc. (\"Old Oncternal\"), GTx, Inc. (\"GTx\") and certain of their subsidiaries, on June 7, 2019 (the \"Effective Time\"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share."}],"balance_after":699406,"source":{"system":"sec-edgar","filing":"0000899243-19-016484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000089924319016484/doc4.xml","form_type":"4"}},{"id":3879284,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-07-02T16:23:23.000Z","date":"2018-06-29","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall be 100% vested and exercisable on June 28, 2019."}],"balance_after":15000,"derivative":{"exercise_price":0.2,"expiration_date":"2028-06-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-040329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919118040329/doc4.xml","form_type":"4"}},{"id":3884309,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T16:04:56.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":4.99,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-18-039395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919118039395/doc4.xml","form_type":"4"}},{"id":4272795,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-26T16:12:41.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":4.96,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-17-041828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919117041828/doc4.xml","form_type":"4"}},{"id":4296523,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-06-02T16:17:12.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall be 100% vested and exercisable on May 2, 2018."}],"balance_after":15000,"derivative":{"exercise_price":1.5,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-037227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919117037227/doc4.xml","form_type":"4"}},{"id":4365543,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-04-03T19:04:43.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":4166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall be 100% vested and exercisable on June 28, 2017."}],"balance_after":4166,"derivative":{"exercise_price":2.13,"expiration_date":"2027-03-30","underlying":"Common Stock","underlying_shares":4166},"source":{"system":"sec-edgar","filing":"0001209191-17-024282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919117024282/doc4.xml","form_type":"4"}},{"id":4576440,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2016-10-21T17:04:05.000Z","date":"2016-10-19","kind":"purchase","acquired":true,"shares":90909,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares were purchased from the issuer in a unit offering, with each unit consisting of one share of Common Stock and one warrant to purchase one share of Common Stock for $1.10 per unit."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Shares were purchased from the issuer in a unit offering, with each unit consisting of one share of Common Stock and one warrant to purchase one share of Common Stock for $1.10 per unit."}],"balance_after":90909,"derivative":{"exercise_price":1.1,"exercise_date":"2016-10-19","expiration_date":"2021-10-19","underlying":"Common Stock","underlying_shares":90909},"source":{"system":"sec-edgar","filing":"0001209191-16-146605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919116146605/doc4.xml","form_type":"4"}},{"id":4576439,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-21T17:04:05.000Z","date":"2016-10-19","kind":"purchase","acquired":true,"shares":90909,"price":1.1,"value":99999.9,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Shares were purchased from the issuer in a unit offering, with each unit consisting of one share of Common Stock and one warrant to purchase one share of Common Stock for $1.10 per unit."}],"balance_after":109099,"source":{"system":"sec-edgar","filing":"0001209191-16-146605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919116146605/doc4.xml","form_type":"4"}},{"id":4576438,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-21T17:04:05.000Z","date":"2016-06-16","kind":"gift","acquired":true,"shares":13334,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As adjusted for the 1-for-3 reverse stock split effected September 27, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On September 27, 2016, the Issuer effected a 1-for-3 reverse stock split resulting in the reporting person's ownership of 33,468 fewer shares."}],"balance_after":16736,"source":{"system":"sec-edgar","filing":"0001209191-16-146605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919116146605/doc4.xml","form_type":"4"}},{"id":4576437,"issuer":{"id":112149,"kind":"organization","name":"BIOCEPT INC","symbol":"BIOC"},"owners":[{"id":70108,"kind":"person","name":"HALE DAVID F","position":1,"cik":"0001024004","reported_name":"HALE DAVID F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-21T17:04:05.000Z","date":"2016-06-16","kind":"gift","acquired":false,"shares":13334,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As adjusted for the 1-for-3 reverse stock split effected September 27, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 27, 2016, the Issuer effected a 1-for-3 reverse stock split resulting in the reporting person's ownership of 36,380 fewer shares."}],"balance_after":18190,"source":{"system":"sec-edgar","filing":"0001209191-16-146605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024004/000120919116146605/doc4.xml","form_type":"4"}}]}